This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for December 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.
What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?
by Zacks Equity Research
Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.
Cumberland Pharmaceuticals (CPIX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.30 in the latest trading session, marking a -1.6% move from the prior day.
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.44 in the latest trading session, marking a -1.72% move from the prior day.
Cumberland Pharmaceuticals (CPIX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $5.67, marking a +1.61% move from the previous day.
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed the most recent trading day at $5.70, moving -1.38% from the previous trading session.
New Strong Buy Stocks for September 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
New Strong Buy Stocks for September 19th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Cumberland (CPIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for September 12th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Theravance Announces Positive Early Data on JAK Inhibitor
by Zacks Equity Research
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
New Strong Buy Stocks for September 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Here is Why Growth Investors Should Buy Cumberland (CPIX) Now
by Zacks Equity Research
Cumberland (CPIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
New Strong Buy Stocks for September 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Here is Why Growth Investors Should Buy Cumberland (CPIX) Now
by Zacks Equity Research
Cumberland (CPIX) could produce exceptional returns because of its solid growth attributes.
Cumberland Pharmaceuticals (CPIX) Q2 Earnings Beat Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 42.86% and -8.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cumberland Pharmaceuticals (CPIX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $6.35, marking a +0.79% move from the previous day.
Why Taro Pharmaceutical (TARO) Could Be Positioned for a Slump
by Zacks Equity Research
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.